Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulia Scartabellati
Observed names:
G. Scartabellati,
Scartabellati, Giulia
Institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
University of Brescia
Observed institutions:
University of Parma,
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
University of Brescia
ORCID:
0000-0001-8787-4699
Observed ORCID:
0000-0001-8787-4699
OpenAlex ID:
A5046324047
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
2022
·
Sebastiano Buti
, Chiara Tommasi
, et al.
·
Anti-Cancer Drugs
·
19
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
2023
·
Federica Villa
, Alessandra Crippa
, et al.
·
International Journal of Molecular Sciences
·
10
PDF
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
2023
·
Chiara Tommasi
, Giulia Scartabellati
, et al.
·
Therapeutic Advances in Urology
·
7
PDF
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
2023
·
Matilde Corianò
, Diana Giannarelli
, et al.
·
Expert Review of Anticancer Therapy
·
4
Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy
2026
·
Rebecca Pedersini
, Laura Moretti
, et al.
·
Breast Cancer Research and Treatment
·
2
Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors
2026
·
Greta Schivardi
, Deborah Cosentini
, et al.
·
JAMA Network Open
·
1
Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/ HER2 ‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study
2026
·
Lara Laini
, Deborah Cosentini
, et al.
·
Cancer Medicine
PDF
Toxicity and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan: Does Body Composition Matter?
2026
·
Giulia Scartabellati
, Benedetta Trevisan
, et al.
·
Research Square
PDF
Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report
2026
·
Benedetta Trevisan
, Deborah Cosentini
, et al.
·
Frontiers in Oncology
PDF
Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer
2026
·
S. Grisanti
, F. Consoli
, et al.
·
The Journal of Liquid Biopsy
PDF
577eP Adipose tissue modifications in patients with advanced breast cancer treated with trastuzumab deruxtecan
2026
·
G. Scartabellati
, B. Trevisan
, et al.
·
ESMO Open
Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen
2026
·
Francesca Piazza
, Giulia Scartabellati
, et al.
·
Frontiers in Oncology
PDF
371P Independent predictive role of obesity on vertebra fracture risk in breast cancer patients undergoing adjuvant aromatase inhibitor therapy
2025
·
G. Schivardi
, E. Dalla Chiara
, et al.
·
Annals of Oncology
402P Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy
2025
·
L. Moretti
, M. Laganà
, et al.
·
ESMO Open
PDF
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
2023
·
Corianò, Matilde
, Giannarelli, Diana
, et al.
·
Figshare
Show more works
View as search
Works count:
18
Citation count:
43
H-index:
4
I10-index:
2
Year
Topic
Type